Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CBLB | Q13191 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12559843 | 0.88 | MTNR1A (0.32) | — | |
| SCHEMBL12559871 | 0.82 | NOS1 (0.31) | — | |
| SCHEMBL12598602 | 0.82 | NOS1 (0.31) | — | |
| SCHEMBL12855200 | 0.73 | VIP (0.40) | CBLB | |
| SCHEMBL12559783 | 0.72 | SCN9A (0.51) | — | |
| SCHEMBL12852189 | 0.72 | SCN9A (0.53) | CBLB | |
| SCHEMBL12559790 | 0.71 | VIP (0.54) | CBLB | |
| SCHEMBL12852200 | 0.71 | VIP (0.54) | CBLB | |
| SCHEMBL13667358 | 0.59 | — | — | |
| SCHEMBL17249604 | 0.58 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7906544-B2 | Dentifrices; stents; catheters; grafts | NORTH CAROLINA STATE UNIVERSITY (US) | 2011-03-15 | — | — | US | disclosed |
| WO-2008094479-A1 | INHIBITION OF BACTERIAL BIOFILMS WITH IMIDAZOLE DERIVATIVES | NORTH CAROLINA STATE UNIVERSITY (US) | 2008-08-07 | — | — | WO | disclosed |
| US-20080181923-A1 | INHIBITION OF BACTERIAL BIOFILMS WITH IMIDAZOLE DERIVATIVES | NORTH CAROLINA STATE UNIVERSITY | 2008-07-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080181923-A1 | INHIBITION OF BACTERIAL BIOFILMS WITH IMIDAZOLE DERIVATIVES | O60361, TFPI, BLVRB | CBLB 2344/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.